TNFSF10, TNF superfamily member 10, 8743

N. diseases: 445; N. variants: 10
Disease: Multiple Sclerosis ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 AlteredExpression disease BEFREE We demonstrate increased levels of many cytokines, including IL-2RA, CCL5, CCL11, MIF, CXCL1, CXCL10, IFNγ, SCF, and TRAIL, were upregulated in cerebrospinal fluid (CSF), whereas IL-17, CCL2, CCL3, CCL4, and IL-12(p40) were activated in MS serum. 28572801 2017
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 AlteredExpression disease BEFREE We examined mRNA expression of the TRAIL and TRAIL receptors variants in patients with MS, at baseline and after one year of IFNβ therapy, according to responsiveness to this drug. 25736057 2016
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 GeneticVariation disease BEFREE In conclusion, no statistical association was found between the Fas, FasL and TRAIL polymorphisms and the risk of MS in Iranian patients. 21864851 2012
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 GeneticVariation disease BEFREE These results suggest that genes of the TRAIL/TRAIL receptor system exerts a genetic influence on MS. 21814551 2011
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 Biomarker disease BEFREE It has recently been reported that tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) plays various roles in such autoimmune diseases as diabetes, multiple sclerosis (MS), and systemic lupus erythematosus (SLE). 18348311 2008
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 AlteredExpression disease LHGDN Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. 16459719 2006
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 AlteredExpression disease BEFREE They included upregulation in MS of orphan nuclear receptor Nurr1 (NR4A2), receptor-interacting serine/threonine kinase 2 (RIPK2), and silencer of death domains (SODD), and downregulation in MS of TNF-related apoptosis-inducing ligand (TRAIL), B-cell CLL/lymphoma 2 (BCL2), and death-associated protein 6 (DAXX). 15755681 2005
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 GeneticVariation disease BEFREE TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. 16040132 2005
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 GeneticVariation disease BEFREE Thus, the TRAIL promoter contains a highly polymorphic area which has, however, no impact on molecule expression, and is neither directly related to increased risk of developing MS nor associated with a certain course of this heterogeneous disease in our population. 15020080 2004
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 Biomarker disease BEFREE TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. 12814715 2003
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.100 Biomarker disease BEFREE Using a soluble TRAIL receptor, we examined the consequences of TRAIL blockade in an animal model of multiple sclerosis. 11145715 2001